Cardiac sarcomere inhibitors
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X, R 1 , R 2 , and R 3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X is —O— or —CH 2 —;
R 1 and R 2 taken together are —CH 2 OC(O)NH—; and
R 3 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —CH 2 —.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —O—.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is methyl, ethyl, propyl, isopropyl, or butyl.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is haloalkyl.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is —CHF 2 .
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is cyclopropyl.
9. A compound selected from the group consisting of
5-(5-ethyl-1,2,4-oxadiazol-3-yl)- 2,3-dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(R)-5-(5-ethyl-1,2,4-oxadiazol-3- yl)-2,3-dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(S)-5-(5-ethyl-1,2,4-oxadiazol-3- yl)-2,3-dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
5-(5-methyl-1,2,4-oxadiazol-3- yl)-2,3-dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(S)-5-(5-methyl-1,2,4-oxadiazol- 3-yl)-2,3-dihydrospiro[indene- 1,4′-oxazolidin]-2′-one;
(R)-5-(5-methyl-1,2,4-oxadiazol- 3-yl)-2,3-dihydrospiro[indene- 1,4′-oxazolidin]-2′-one;
5-(5-isopropyl-1,2,4-oxadiazol-3- yl)-2,3-dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(R)-5-(5-isopropyl-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(S)-5-(5-isopropyl-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
5-(5-cyclopropyl-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(S)-5-(5-cyclopropyl-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(R)-5-(5-cyclopropyl-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
5-(5-(difluoromethyl)-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(R)-5-(5-(difluoromethyl)-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
(S)-5-(5-(difluoromethyl)-1,2,4- oxadiazol-3-yl)-2,3- dihydrospiro[indene-1,4′- oxazolidin]-2′-one;
6-(5-ethyl-1,2,4-oxadiazol-3-yl)- 2H-spiro[benzofuran-3,4′- oxazolidin]-2′-one;
(S)-6-(5-ethyl-1,2,4-oxadiazol-3- yl)-2H-spiro[benzofuran-3,4′- oxazolidin]-2′-one; and
(R)-6-(5-ethyl-1,2,4-oxadiazol-3- yl)-2H-spiro[benzofuran-3,4′- oxazolidin]-2′-one;
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
11. A method of treating heart disease in a subject in need thereof, comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the heart disease is hypertrophic cardiomyopathy.
13. The method of claim 12 , wherein the hypertrophic cardiomyopathy is obstructive or nonobstructive or is caused by sarcomeric and/or non-sarcomeric mutations.
14. The method of claim 11 , wherein the heart disease is heart failure with preserved ejection fraction.
15. The method of claim 11 , wherein the heart disease is selected from the group consisting of diastolic dysfunction, primary or secondary restrictive cardiomyopathy, myocardial infarction, angina pectoris, left ventricular outflow tract obstruction, hypertensive heart disease, congenital heart disease, cardiac ischemia, coronary heart disease, diabetic heart disease, congestive heart failure, right heart failure, cardiorenal syndrome, and infiltrative cardiomyopathy.
16. The method of claim 11 , wherein the heart disease is or is related to one or more conditions selected from the group consisting of cardiac senescence, diastolic dysfunction due to aging, left ventricular hypertrophy and concentric left ventricular remodeling.
17. A method of treating a disease or condition that is associated with small left ventricular cavity, cavity obliteration, hyperdynamic left ventricular contraction, myocardial ischemia, or cardiac fibrosis in a subject in need thereof, comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
18. A method of inhibiting a cardiac sarcomere, comprising contacting the cardiac sarcomere with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.